Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis
David A Palma, Suresh Senan, Cary Oberije, Jose Belderbos, Nuria Rodriguez de Dios, Jeffrey D Bradley, R Bryan Barriger, Marta Moreno-Jimenez, Tae Hyun Kim, Sara Ramella, Sarah Everitt, Ramesh Rengan, Lawrence B Marks, Kim De Ruyck, Andrew Warner, George Rodrigues
International Journal of Radiation: Oncology - Biology - Physics | ELSEVIER SCIENCE INC | Published : 2013
Awarded by NATIONAL CANCER INSTITUTE
Dr Senan has received research funding from Sanofi-Aventis and is a member of the trial management group (not reimbursed) for the phase 3 PROCLAIM study evaluating concurrent chemoradiation therapy schemes for stage III lung cancer, which is sponsored by Eli Lilly. Dr Barriger holds a leadership position with D3 Oncology Solutions, is a member of the Via Oncology Pathways Physician Advisory Committee, and is the Radiation Oncology Esophageal and Lung (Small Cell and Non-Small Cell) Committee Co-Chair. The authors report no other conflict of interest.